HGD

Across TCGA pan-cancer cohorts, HGD Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HGD data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher HGD Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HGD expression acts as an unfavorable survival marker.

LIHC, COAD, and HNSC are the cancer types where HGD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	III,IV	0.051	0.738	<.001	12	view →
COAD	OS	Median	All	0.134	0.809	<.001	12	view →
HNSC	OS	Median	III,IV	0.155	0.656	.022	6	view →
SKCM	OS	Median	IV	0.179	0.755	<.001	6	view →
LUAD	OS	Median	All	0.301	0.698	.045	3	view →
LGG	OS	Median	All	0.611	0.889	.007	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HGD–LIHC (OS)

Open the LIHC breakdown →